Home Healthcare Pharmaceuticals Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Size, Share & Trends Analysis Report By Drug Type (Pharmaceuticals, Biologics & Biosimilars), By Sales Channel (Prescription, Over-the-Counter) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 28, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Rheumatoid Arthritis Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Pharmaceuticals
      1. Non-steroidal Anti-inflammatory Drugs
      2. Corticosteroids
      3. Analgesics
      4. Others
    2. Biologics & Biosimilars
      1. TNF-α antagonists
      2. T-cell inhibitors
      3. CD20 antigen
      4. JAK inhibitors
      5. Others
  2. Rheumatoid Arthritis Market, By Sales Channel 2022-2034 (USD MILLION/ Units)
    1. Prescription
    2. Over-the-Counter
  3. Regional Rheumatoid Arthritis Market
    1. North America
      1. North America Rheumatoid Arthritis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
      2. North America Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription
        2. Over-the-Counter
      3. U.S.
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      4. Canada
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
    2. Europe
      1. Europe Rheumatoid Arthritis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
      2. Europe Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription
        2. Over-the-Counter
      3. U.K.
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      4. Germany
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      5. France
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      6. Spain
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      7. Italy
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      8. Russia
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      9. Nordic
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      10. Benelux
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      11. Rest of Europe
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
    3. APAC
      1. APAC Rheumatoid Arthritis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
      2. APAC Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription
        2. Over-the-Counter
      3. China
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      4. Korea
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      5. Japan
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      6. India
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      7. Australia
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      8. Singapore
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      9. Taiwan
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      10. South East Asia
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      11. Rest of Asia-Pacific
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
    4. Middle East and Africa
      1. Middle East and Africa Rheumatoid Arthritis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
      2. Middle East and Africa Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription
        2. Over-the-Counter
      3. UAE
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      4. Turkey
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      5. Saudi Arabia
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      6. South Africa
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      7. Egypt
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      8. Nigeria
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      9. Rest of MEA
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
    5. LATAM
      1. LATAM Rheumatoid Arthritis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
      2. LATAM Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription
        2. Over-the-Counter
      3. Brazil
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      4. Mexico
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      5. Argentina
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      6. Chile
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      7. Colombia
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
      8. Rest of LATAM
        1. Pharmaceuticals
          1. Non-steroidal Anti-inflammatory Drugs
          2. Corticosteroids
          3. Analgesics
          4. Others
        2. Biologics & Biosimilars
          1. TNF-α antagonists
          2. T-cell inhibitors
          3. CD20 antigen
          4. JAK inhibitors
          5. Others
        3. Prescription
        4. Over-the-Counter
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.